相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses
Leila N. Varghese et al.
BIOCHEMICAL JOURNAL (2014)
A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties
James M. Murphy et al.
BIOCHEMICAL JOURNAL (2014)
Genomic Profiling of Hepatocellular Adenomas Reveals Recurrent FRK-Activating Mutations and the Mechanisms of Malignant Transformation
Camilla Pilati et al.
CANCER CELL (2014)
Tofacitinib for acute rheumatoid arthritis patients who have had an inadequate response to disease-modifying antirheumatic drug (DMARD): a systematic review and meta-analysis
Xingming Zhang et al.
CLINICAL RHEUMATOLOGY (2014)
Selective deletion of Jak2 in adult mouse hematopoietic cells leads to lethal anemia and thrombocytopenia
Jean Grisouard et al.
HAEMATOLOGICA (2014)
Structural basis of recognition of interferon-α receptor by tyrosine kinase 2
Heidi J. A. Wallweber et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2014)
Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition
Patrick J. Lupardus et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Mechanism of Activation of Protein Kinase JAK2 by the Growth Hormone Receptor
Andrew J. Brooks et al.
SCIENCE (2014)
Critical Role of Jak2 in the Maintenance and Function of Adult Hematopoietic Stem Cells
Hajime Akada et al.
STEM CELLS (2014)
Conditional ablation of TYK2 in immunity to viral infection and tumor surveillance
Raimund M. Vielnascher et al.
TRANSGENIC RESEARCH (2014)
SUMOylation is a regulator of the translocation of Jak2 between nucleus and cytosol
Magdalena Sedek et al.
BIOCHEMICAL JOURNAL (2013)
Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project
Mignon L. Loh et al.
BLOOD (2013)
The Pseudokinase MLKL Mediates Necroptosis via a Molecular Switch Mechanism
James M. Murphy et al.
IMMUNITY (2013)
Structure-guided studies of the SHP-1/JAK1 interaction provide new insights into phosphatase catalytic domain substrate recognition
Nilda L. Alicea-Velazquez et al.
JOURNAL OF STRUCTURAL BIOLOGY (2013)
On the Regulation and Activation of JAK2: A Novel Hypothetical Model
Tai-Sung Lee
MOLECULAR CANCER RESEARCH (2013)
Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases
Angela V. Toms et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2013)
SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition
Nadia J. Kershaw et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2013)
Conditional Deletion of Jak2 Reveals an Essential Role in Hematopoiesis throughout Mouse Ontogeny: Implications for Jak2 Inhibition in Humans
Sung O. Park et al.
PLOS ONE (2013)
Lnk adaptor suppresses radiation resistance and radiation-induced B-cell malignancies by inhibiting IL-11 signaling
Igal Louria-Hayon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia
Michael Porcu et al.
BLOOD (2012)
The biology and mechanism of action of suppressor of cytokine signaling 3
Jeffrey J. Babon et al.
GROWTH FACTORS (2012)
Genotype-Phenotype Interactions in the Myeloproliferative Neoplasms
Anna L. Godfrey et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2012)
Suppression of Cytokine Signaling by SOCS3: Characterization of the Mode of Inhibition and the Basis of Its Specificity
Jeffrey J. Babon et al.
IMMUNITY (2012)
A Patient with Tyrosine Kinase 2 Deficiency without Hyper-IgE Syndrome
Sara S. Kilic et al.
JOURNAL OF PEDIATRICS (2012)
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
Priya Koppikar et al.
NATURE (2012)
Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F
Rajintha M. Bandaranayake et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations
Francesco Passamonti et al.
BLOOD (2011)
Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group
Jinghui Zhang et al.
BLOOD (2011)
PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia
Maria Kleppe et al.
BLOOD (2011)
JAKs go nuclear: Emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth
Fouad A. Zouein et al.
GROWTH FACTORS (2011)
The role of the N-terminal domain in dimerization and nucleocytoplasmic shuttling of latent STAT3
Michael Vogt et al.
JOURNAL OF CELL SCIENCE (2011)
The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling
Daniela Ungureanu et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
Structural Snapshots of Full-Length Jak1, a Transmembrane gp130/IL-6/IL-6Rα Cytokine Receptor Complex, and the Receptor-Jak1 Holocomplex
Patrick J. Lupardus et al.
STRUCTURE (2011)
PTP1B Suppresses Prolactin Activation of Stat5 in Breast Cancer Cells
Kevin J. Johnson et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms
Stephen T. Oh et al.
BLOOD (2010)
Oncogenic JAK2V617F requires an intact SH2-like domain for constitutive activation and induction of a myeloproliferative disease in mice
Sivahari P. Gorantla et al.
BLOOD (2010)
Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms
Fanny Baran-Marszak et al.
BLOOD (2010)
Tyrosines 868, 966, and 972 in the Kinase Domain of JAK2 Are Autophosphorylated and Required for Maximal JAK2 Kinase Activity
Lawrence S. Argetsinger et al.
MOLECULAR ENDOCRINOLOGY (2010)
Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia
Maria Kleppe et al.
NATURE GENETICS (2010)
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
JAK2 V617F Constitutive Activation Requires JH2 Residue F595: A Pseudokinase Domain Target for Specific Inhibitors
Alexandra Dusa et al.
PLOS ONE (2010)
A JAK2 Interdomain Linker Relays Epo Receptor Engagement Signals to Kinase Activation
Lequn Zhao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Mutation Profile of JAK2 Transcripts in Patients with Chronic Myeloproliferative Neoplasias
Wanlong Ma et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2009)
Regulation of Jak2 Function by Phosphorylation of Tyr317 and Tyr637 during Cytokine Signaling
Scott A. Robertson et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin
Mark A. Dawson et al.
NATURE (2009)
JAK mutations in high-risk childhood acute lymphoblastic leukemia
Charles G. Mullighan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes
Gerlincle Wernig et al.
BLOOD (2008)
Negative regulation of Jak2 by its auto-phosphorylation at tyrosine 913 via the Epo signaling pathway
Megumi Funakoshi-Tago et al.
CELLULAR SIGNALLING (2008)
Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers
Eun Goo Jeong et al.
CLINICAL CANCER RESEARCH (2008)
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia
Elisabetta Flex et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome
Dani Bercovich et al.
LANCET (2008)
Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F
Xiaohui Lu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
Klarisa Rikova et al.
CELL (2007)
The N-terminal SH2 domain of the tyrosine phosphatase, SHP-2, is essential for Jak2-dependent signaling via the angiotensin II type AT1 receptor
Michael D. Godeny et al.
CELLULAR SIGNALLING (2007)
Lnk negatively regulates self-renewal of hematopoietic stem cells by modifying thrombopoietin-mediated signal transduction
Jun Seita et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase
Rebecca J. Chan et al.
BLOOD (2007)
Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain:: D620E and E627E
S. Schnittger et al.
LEUKEMIA (2006)
Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera
F. Gruenebach et al.
LEUKEMIA (2006)
Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity
Yoshiyuki Minegishi et al.
IMMUNITY (2006)
Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2
Megumi Funakoshi-Tago et al.
EMBO JOURNAL (2006)
Binding of SH2-B family members within a potential negative regulatory region maintains JAK2 in an active state
Jason H. Kurzer et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Cytokines regulate postnatal hematopoietic stem cell expansion: opposing roles of thrombopoietin and LNK
Natalija Buza-Vidas et al.
GENES & DEVELOPMENT (2006)
Activating alleles of JAK3 in acute megakaryoblastic leukemia
Denise K. Walters et al.
CANCER CELL (2006)
The human and mouse complement of SH2 domain proteins -: Establishing the boundaries of phosphotyrosine signaling
Bernard A. Liu et al.
MOLECULAR CELL (2006)
Phosphorylation of JAK2 at serine 523: a negative regulator of JAK2 that is stimulated by growth hormone and epidermal growth factor
Anna M. Mazurkiewicz-Munoz et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Phosphorylation of Jak2 on Ser523 inhibits Jak2-dependent leptin receptor signaling
Ryoko Ishida-Takahashi et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
The structure of SOCS3 reveals the basis of the extended SH2 domain function and identifies an unstructured insertion that regulates stability
JJ Babon et al.
MOLECULAR CELL (2006)
Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-β1
I Kinjyo et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-β1 production
H Ogata et al.
ONCOGENE (2006)
The JAK2 V617F mutation in de novo acute myelogenous leukemias
JW Lee et al.
ONCOGENE (2006)
Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia
CP Kratz et al.
LEUKEMIA (2006)
The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor
IS Lucet et al.
BLOOD (2006)
Secondary structure assignment of mouse SOCS3 by NMR defines the domain boundaries and identifies an unstructured insertion in the SH2 domain
JJ Babon et al.
FEBS JOURNAL (2005)
The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene
M Bousquet et al.
ONCOGENE (2005)
A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q 11.2) translocation in a patient with a clinically typical chronic myeloid leukemia
F Griesinger et al.
GENES CHROMOSOMES & CANCER (2005)
Identification of an acquired JAK2 mutation in Polycythemia vera
RX Zhao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways
W Tong et al.
BLOOD (2005)
Quantification of self-renewal capacity in single hematopoietic stem cells from normal and lnk-deficient mice
H Ema et al.
DEVELOPMENTAL CELL (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2
A Reiter et al.
CANCER RESEARCH (2005)
Mechanism of protein tyrosine phosphatase 1B-mediated inhibition of leptin signalling
IK Lund et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation of JAK2 by SH2-Bβ
JH Kurzer et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Tyrosine phosphorylation of the Janus kinase 2 activation loop is essential for a high-activity catalytic state but dispensable for a basal catalytic state
K Chatti et al.
BIOCHEMISTRY (2004)
SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma:: implications for epigenetic activation of the Jak/STAT pathway
CS Chim et al.
LEUKEMIA (2004)
SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis
BA Croker et al.
IMMUNITY (2004)
Analysis of Stat3 (signal transducer and activator of transcription 3) dimerization by fluorescence resonance energy transfer in living cells
AK Kretzschmar et al.
BIOCHEMICAL JOURNAL (2004)
Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis
W Tong et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Generation of a conditional knockout allele for the Janus kinase 2 (Jak2) gene in mice
A Krempler et al.
GENESIS (2004)
Determination of the transphosphorylation sites of Jak2 kinase
T Matsuda et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Jak3 and the pathogenesis of severe combined immunodeficiency
JJ O'Shea et al.
MOLECULAR IMMUNOLOGY (2004)
Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity
H Mori et al.
NATURE MEDICINE (2004)
SOCS1 and SHP1 hypermethylation in multiple myeloma:: implications for epigenetic activation of the Jak/STAT pathway
CS Chim et al.
BLOOD (2004)
Impaired alveologenesis and maintenance of secretory mammary epithelial cells in Jak2 conditional knockout mice
KU Wagner et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity
LS Argetsinger et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling
EP Feener et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity
MH Shaw et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
STATs dimerize in the absence of phosphorylation
J Braunstein et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages
H Yasukawa et al.
NATURE IMMUNOLOGY (2003)
SOCS3 negatively regulates IL-6 signaling in vivo
BA Croker et al.
NATURE IMMUNOLOGY (2003)
Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock
M Karaghiosoff et al.
NATURE IMMUNOLOGY (2003)
The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction
P Saharinen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice
L Velazquez et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
PTP1B regulates leptin signal transduction in vivo
JM Zabolotny et al.
DEVELOPMENTAL CELL (2002)
Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B
A Cheng et al.
DEVELOPMENTAL CELL (2002)
The T cell protein tyrosine phosphatase is a negative regulator of janus family kinases 1 and 3
PD Simoncic et al.
CURRENT BIOLOGY (2002)
SH2-B family members differentially regulate JAK family tyrosine kinases
KB O'Brien et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
M Tartaglia et al.
NATURE GENETICS (2001)
Neutralization of interferon-γ in neonatal SOCS1-/- mice prevents fatty degeneration of the liver but not subsequent fatal inflammatory disease
DVR Bullen et al.
IMMUNOLOGY (2001)
Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3
AW Roberts et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Targeted and extended acetylation of histones H4 and H3 at active and inactive genes in chicken embryo erythrocytes
FA Myers et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling
J Irie-Sasaki et al.
NATURE (2001)
JAB/SOCS1/SSI-1 is an interleukin-2-induced inhibitor of IL-2 signaling
B Sporri et al.
BLOOD (2001)
Control of B cell production by the adaptor protein Lnk: Definition of a conserved family of signal-modulating proteins
S Takaki et al.
IMMUNITY (2000)
Tyk2 plays a restricted role in IFNα signaling, although it is required for IL-12-mediated T cell function
K Shimoda et al.
IMMUNITY (2000)
Partial impairment of cytokine responses in Tyk2-deficient mice
M Karaghiosoff et al.
IMMUNITY (2000)
Regulation of the Jak2 tyrosine kinase by its pseudokinase domain
P Saharinen et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)